UBS Group
ACTU

UBS Group’s Actuate Therapeutics ACTU Stock Holding History

UBS Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.35K Sell
1,951
-3,170
-62% -$13.1K ﹤0.01% 8800
2025
Q4 		$31.3K Sell
5,121
-3,806
-43% -$26.1K ﹤0.01% 7501
2025
Q3 		$59.7K Buy
8,927
+6,580
+280% +$47.7K ﹤0.01% 7440
2025
Q2 		$14.3K Buy
2,347
+368
+19% +$3.21K ﹤0.01% 8657
2025
Q1 		$13.4K Buy
1,979
+45
+2% +$361 ﹤0.01% 8463
2024
Q4 		$15.4K Buy
+1,934
New +$15.8K ﹤0.01% 8048

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's ACTU Position: Q1 2026 in Review

UBS Group reduced its Actuate Therapeutics (ACTU) stake by 62% in Q1 2026, selling an estimated $13.1K and leaving 1,951 shares worth $5.35K. The position accounts for ﹤0.01% of the portfolio, ranked #8800.

UBS Group first reported a position in ACTU in Q4 2024 and has held it in 6 quarters since. The position peaked at $59.7K in Q3 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • UBS Group held 1,951 shares of Actuate Therapeutics worth $5.35K as of Q1 2026.
  • UBS Group sold 3,170 Actuate Therapeutics shares in Q1 2026, an estimated $13.1K.
  • Actuate Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8800 holding.
  • UBS Group first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • UBS Group's Actuate Therapeutics position peaked at $59.7K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.